Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Acquire High-Throughput Screening Shop Evotec Tech for $30.5M

NEW YORK (GenomeWeb News) — PerkinElmer plans to acquire high-throughput screening Evotec Technologies for €23 million ($30.5 million) in cash, German parent company Evotec said late yesterday.
 
Evotec makes and sells tools for high-throughput and high-content cell and biochemical screening. PerkinElmer CEO Gregory Summe said in a statement that the acquisition will “help our customers speed target validations and lead optimization along the drug discovery value chain.”
 
Evotec Tech CEO Carsten Claussen said that “this is the time to exploit our potential as part of a larger entity with a significantly broader sales force, portfolio strategy, and R&D resources.”
 
Parent Evotec said the move is part of its strategy to focus the company on drug development, and said the proceeds from the sale will help fund its central nervous system pipeline.
 
The companies expect the deal to close in late December or early 2007. It is subject to shareholder approval and to other closing conditions.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.